<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>333</serviceExecutionTime><Drug id="45462"><DrugName>propofol (lingual spray formulation), Manhattan/NovaDel</DrugName><DrugNamesKey><Name id="42751826">propofol</Name></DrugNamesKey><DrugSynonyms><Name><Value>propofol</Value><Types><Type>USAN</Type><Type>BANN</Type><Type>INN</Type></Types></Name><Name><Value>propofol (lingual spray formulation), Manhattan/NovaDel</Value></Name><Name><Value>2078-54-8</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="31093">TG Therapeutics Inc</CompanyOriginator><CompaniesSecondary><Company id="27787">NovaDel Pharma Inc</Company><Company id="31093">TG Therapeutics Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="27787" type="Company"><TargetEntity id="4295913503" type="organizationId">Novadel Pharma Inc</TargetEntity></SourceEntity><SourceEntity id="31093" type="Company"><TargetEntity id="4295912581" type="organizationId">TG Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="19" type="ciIndication"><TargetEntity id="10002091" type="MEDDRA"></TargetEntity><TargetEntity id="D000758" type="MeSH"></TargetEntity><TargetEntity id="-564538434" type="omicsDisease"></TargetEntity><TargetEntity id="23" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C1">Phase 1 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="19">Anesthesia</Indication></IndicationsSecondary><ActionsSecondary><Action id="1667">Anesthetic</Action><Action id="2942">Anxiolytic</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="680">Buccal formulation systemic</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N1</Code><Name>ANAESTHETICS</Name></Ephmra><Ephmra><Code>N5C</Code><Name>TRANQUILLISERS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-28T10:35:38.000Z</LastModificationDate><ChangeDateLast>2011-12-30T04:21:59.000Z</ChangeDateLast><AddedDate>2003-06-19T16:23:51.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="27787" linkType="Company"&gt;NovaDel Pharma&lt;/ulink&gt; was developing  a lingual spray formulation of the anesthetic propofol (structure shown), as a potential pre-procedural sedative [&lt;ulink linkID="494094" linkType="reference"&gt;494094&lt;/ulink&gt;]. By July 2004, a UK phase I trial had been completed  [&lt;ulink linkID="548873" linkType="Reference"&gt;548873&lt;/ulink&gt;]. In January 2005, the FDA approved an IND for the drug [&lt;ulink linkID="582140" linkType="Reference"&gt;582140&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;ulink linkID="31093" linkType="Company"&gt;Manhattan Pharmaceuticals&lt;/ulink&gt; was previously collaborating on the development of the formulation, however, in July 2007 the company discontinued development and was seeking to outlicense the drug [&lt;ulink linkID="883113" linkType="Reference"&gt;883113&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In July 2004, Manhattan reported results from phase I trials of the spray. The UK-based, single center, randomized, double-blind, placebo-controlled dose-escalating study in 12 patients compared the safety and tolerability of three doses of propofol spray to a single iv bolus low dose of propofol. No adverse events or dose-dependent changes in vital signs were observed in any group. The mean time to maximum blood concentration of propofol following spray was 30 min across all doses and propofol was detectable in blood 4 min after administration. The maximum blood concentrations plateaued at the highest of the three doses tested, and the bioavailability of the spray formulation was up to 18% of that of the iv formulation [&lt;ulink linkID="548873" linkType="Reference"&gt;548873&lt;/ulink&gt;]. Following the results, Manhattan directed NovaDel to optimize the dose and formulation, resulting in the support of an IND, which was accepted in January 2005 [&lt;ulink linkID="582140" linkType="Reference"&gt;582140&lt;/ulink&gt;], [&lt;ulink linkID="642347" linkType="Reference"&gt;642347&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In April 2004, Manhattan presented preclinical data for its propofol lingual spray at the 19th Annual Meeting of the Society for Ambulatory Anesthesia, in Seattle, WA. Manhattan tested spray uniformity, pattern, angle, content, volume, and droplet size distribution of the formulation, before and after standard long-term, as well as accelerated, stability conditions. The formulation was packaged in single-dose actuators designed to deliver a fine mist to the oral mucous membranes. All spray parameters remained within specifications, indicating that the formulation was stable [&lt;ulink linkID="535630" linkType="reference"&gt;535630&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;By June 2003, Manhattan and NovaDel had begun a co-development program for propofol lingual spray. Under the agreement, Manhattan obtained worldwide exclusive rights to use NovaDel's proprietary spray technology [&lt;ulink linkID="494045" linkType="reference"&gt;494045&lt;/ulink&gt;]. In July 2007, Manhattan discontinued development of the drug and was seeking to outlicense rights to the drug [&lt;ulink linkID="883113" linkType="Reference"&gt;883113&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="31093">TG Therapeutics Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="19">Anesthesia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-07-09T00:00:00.000Z</StatusDate><Source id="883113" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="31093">TG Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="19">Anesthesia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-07-09T00:00:00.000Z</StatusDate><Source id="883113" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27787">NovaDel Pharma Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="19">Anesthesia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-12-29T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="27787">NovaDel Pharma Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="19">Anesthesia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-06-14T00:00:00.000Z</StatusDate><Source id="548873" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="31093">TG Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="19">Anesthesia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-06-18T00:00:00.000Z</StatusDate><Source id="494094" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="31093">TG Therapeutics Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="19">Anesthesia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-06-14T00:00:00.000Z</StatusDate><Source id="548873" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="27787">NovaDel Pharma Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="31093">TG Therapeutics Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CC(C)c1cccc(c1O)C(C)C</Smiles></StructureSmiles><Deals><Deal id="125288" title="Manhattan to codevelop NovaDel's worldwide propofol lingual spray"></Deal></Deals><PatentFamilies><PatentFamily id="254162" number="WO-2005105042" title="Buccal, polar and non-polar sprays containing propofol"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Velcera Pharmaceuticals" id="1022613"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="NovaDel Pharma Inc" id="27787"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="TG Therapeutics Inc" id="31093"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput>